Risk of Delays in R&D Outcomes, Uncertainty and Failure to Secure Adoption
First written in FY2017. 5 of 8 entries say "Restated". Latest entry: FY2022.
The whole theme swung hardest in 2026: 14 of 29 companies on the "Worse" side.
74 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「If the expected results are not achieved as planned, development may need to be extended or discontinued, investment may increase, or the product may ultimately fail to reach commercialization. Even if a product is commercialized, various uncertainties mean that customer adoption cannot be assured.」
The Company has reaffirmed the risks of prolonged research and development, increased investment, failure to commercialize products and failure to secure customer adoption. - FY2022-Q3RestatedAnnual report
「Although some signs of recovery have appeared in repeat orders, the impact of delays to new-product planning remains significant」
The Company states that while the postponement of new product planning continues to be a factor behind lower sales, some recovery has been seen in repeat orders. - FY2022-Q2RestatedAnnual report
「④ The impact of postponing new product planning remained significant」
The postponement of new product planning continues to have a significant impact as a factor behind lower sales. - FY2022-Q1RestatedAnnual report
「④ The impact of postponing new product planning remained significant」
The postponement of new product planning continues to affect sales as a delay in research and development and commercialization. - FY2021MaterialisedAnnual report
「Net sales for the consolidated fiscal year were significantly affected by (1) lower consumer demand for makeup cosmetics due to restrictions on going out and the normalization of mask wearing as measures against COVID-19, (2) a sharp decline in inbound demand from visitors to Japan, (3) lower orders for products for overseas markets due to the global spread of COVID-19, and (4) the postponement of new product planning,」
The postponement of new product planning was specifically cited as an actual factor behind the full-year decline in sales related to the risk of delays in research and development and commercialization. - FY2021-Q3MaterialisedAnnual report
「④ The impact of postponing new product planning was significant」
Regarding the risk of delays in research and development and commercialization, the Company reported the specific impact of postponing new product planning. - FY2018RestatedAnnual report
「If the expected results are not achieved, the Company may be forced to extend or discontinue the project, increase the investment amount, or may ultimately be unable to commercialize the product.」
The Company has reaffirmed the risks of prolonged research and development, increased investment, failure to commercialize products and failure to secure customer adoption. - FY2017First statedAnnual report
「If the expected results are not achieved as planned, development may need to be extended or discontinued, investment may increase, or the product may ultimately fail to reach commercialization. Even if a product is commercialized, various uncertainties mean that customer adoption cannot be assured.」
The Company identifies prolonged R&D, increased investment, failure to commercialize products and failure to secure customer adoption as related risks.